State-backed ElectroMobility Poland said Thursday it will partner with Taiwan's Foxconn to develop an electric vehicle production and research hub in southern Poland, advancing plans to create a domestic EV champion as Europe demand picks up.
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that the US Patent and Trademark Office has granted a new patent covering EMP-01, its oral R-MDMA formulation. The company said that the patent includes claims to the drug substance of EMP-01 and is expected to provide exclusivity through 2043.
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first patient in its Phase 2 clinical trial of EMP-01 for the treatment of social anxiety disorder (SAD). EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine, is being investigated in an exploratory, randomized, double-blind, placebo-controlled study involving approximately 60 adult participants with SAD.